Palatin Technologies (PTN) Enterprise Value (2010 - 2026)
Palatin Technologies' (PTN) quarterly Enterprise Value came in at -$10.2 million in Q1 2026, down 303.14% YoY from $5.0 million in Q1 2025, and up 29.82% on a QoQ basis from -$14.5 million in Q4 2025.
Palatin Technologies (PTN) Enterprise Value (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Enterprise Value data on file, last reported at -$10.2 million in Q1 2026.
- Quarterly Enterprise Value fell 303.14% year-over-year to -$10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.2 million (down 303.14% YoY) and the FY2025 annual result came in at -$2.6 million, up 73.09% from the prior year.
- Enterprise Value advanced to -$10.2 million in Q1 2026, from -$14.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.3 million in Q3 2025 to a low of -$37.7 million in Q1 2022.
- A 5-year average of -$12.5 million and a median of -$10.0 million in 2024 frame the typical range for Enterprise Value.
- The widest YoY moves for Enterprise Value: up 74.83% in 2025, down 323.7% in 2025.
- Tracing PTN's Enterprise Value over 5 years: stood at -$21.2 million in 2022, then jumped by 55.22% to -$9.5 million in 2023, then surged by 63.98% to -$3.4 million in 2024, then slumped by 323.7% to -$14.5 million in 2025, then increased by 29.82% to -$10.2 million in 2026.
- The last three Enterprise Value figures came in at -$10.2 million (Q1 2026), -$14.5 million (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Palatin Technologies | 40.86 Mn | 40.86 Mn | - | -10.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.16 Mn |
| Dec 31, 2025 | -14.48 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -2.56 Mn |
| Mar 31, 2025 | -2.52 Mn |
| Dec 31, 2024 | -3.42 Mn |
| Sep 30, 2024 | -2.38 Mn |
| Jun 30, 2024 | -9.53 Mn |
| Mar 31, 2024 | -10.01 Mn |
| Dec 31, 2023 | -9.49 Mn |
| Sep 30, 2023 | -5.52 Mn |
| Jun 30, 2023 | -10.98 Mn |
| Mar 31, 2023 | -19.63 Mn |
| Dec 31, 2022 | -21.18 Mn |
| Sep 30, 2022 | -21.19 Mn |
| Jun 30, 2022 | -29.94 Mn |
| Mar 31, 2022 | -37.72 Mn |
| Dec 31, 2021 | -47.33 Mn |
| Sep 30, 2021 | -52.55 Mn |
| Jun 30, 2021 | -60.10 Mn |